Pharosyn, a startup building AI infrastructure for commercial decision-making in pharma, has raised £2.2 million in a fundraising round led by Moonfire. Entrepreneurs First, Transpose Platform and General Advance also invested.
Pharosyn is built on two convictions: that pharmaceutical companies need custom AI infrastructure to maintain a competitive advantage, and that embedding this infrastructure deep inside pharma teams can improve commercial decision-making. By dramatically increasing the depth of insight, scope of analysis and speed at which teams can work, Pharosyn helps companies make better decisions about where to allocate resources. Its infrastructure can be deployed across commercial strategy, portfolio strategy, business development and licensing, market research, forecasting and competitive intelligence.
Months of deployment work have taken that infrastructure deep into pharmaceutical commercial strategy workflows. Senior directors at top-10 pharmaceutical companies now use Pharosyn every single day to inform major strategic decisions. Critical insights are reaching senior decision-makers that would otherwise have been missed, and important questions are answered in minutes instead of hours, with faster iteration creating compounding feedback loops and deeper analysis every week.
Founded by Stephen Cowley and Joshua Hampson, Pharosyn draws on Cambridge University backgrounds in AI research and biochemistry, with both founders ranking in the top 5% of their cohorts. The wider team carries years of engineering experience deploying AI in financial forecasting and enterprise productivity, alongside decades of senior executive experience consulting in pharmaceutical commercial strategy at Citeline and leading consulting firms.
Pharosyn's founders are deeply technical, exceptionally tenacious and ambitious, and determined to be best-in-class globally. They are rare founders who clearly stand out. We could not be more excited to lead this round.
